Ethinylestradiol

DRUG5 trials

Sponsors

Boehringer Ingelheim, Manuel Luque Ramírez, Janssen Research & Development, LLC, Janssen Pharmaceutica N.V., Belgium

Conditions

HealthyHealthy FemaleHepatitis C, ChronicHyperandrogenismMetabolic Cardiovascular Syndrome

Phase 1

Drug-drug Interaction of Empagliflozin (BI 10773) and Microgynon

CompletedNCT01328184

Boehringer IngelheimHealthy

Start: 2011-04-30Updated: 2014-06-18

Drug-drug Interaction of BI 201335 and Microgynon

CompletedNCT01570244

Boehringer IngelheimHepatitis C, Chronic

Start: 2012-04-30End: 2012-08-31Updated: 2015-08-03

A Study to Investigate the Effect of JNJ-63623872 at Steady-state on the Steady-state Pharmacokinetics of Ethinylestradiol and Norethindrone

CompletedNCT02652650

Janssen Research & Development, LLCHealthy

Start: 2015-12-31End: 2016-06-30Updated: 2016-06-06

A Study of Milvexian in Healthy Adult Females

CompletedNCT05706753

Janssen Pharmaceutica N.V., BelgiumHealthy Female

Start: 2023-01-25End: 2023-07-20Updated: 2025-03-30

Unknown Phase

Phlebotomy and Polycystic Ovary Syndrome

CompletedNCT02460445

Manuel Luque RamírezHyperandrogenism, Metabolic Cardiovascular Syndrome

Start: 2015-01-31End: 2020-06-30Updated: 2022-07-27

Related Papers

Bloodletting has no effect on the blood pressure abnormalities of hyperandrogenic women taking oral contraceptives in a randomized clinical trial.

2021-11-11

Effect of the Hepatitis C Virus Protease Inhibitor Faldaprevir on the Pharmacokinetics of an Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel in Healthy Female Volunteers

Antimicrobial Agents and Chemotherapy2014-11-116 citations